(Q42631756)

English

Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study

scientific article published on January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study (English)

1 reference

Europe PubMed Central

4 November 2017

0 references

Reiji Yoshimura

3

object named as

Reiji Yoshimura

1 reference

Europe PubMed Central

4 November 2017

9

object named as

Jun Nakamura

1 reference

Europe PubMed Central

4 November 2017

2

object named as

Nobuhisa Ueda

1 reference

Europe PubMed Central

4 November 2017

1

object named as

Hikaru Hori

1 reference

Europe PubMed Central

4 November 2017

author name string

Hiroshi Yamamoto

4

1 reference

Europe PubMed Central

4 November 2017

Kenta Wani

5

1 reference

Europe PubMed Central

4 November 2017

Yoshinori Etoh

6

1 reference

Europe PubMed Central

4 November 2017

Kensuke Haraga

7

1 reference

Europe PubMed Central

4 November 2017

Junichi Kitahara

8

1 reference

Europe PubMed Central

4 November 2017

publication date

1 January 2009

1 reference

Europe PubMed Central

4 November 2017

World Journal of Biological Psychiatry

1 reference

Europe PubMed Central

4 November 2017

10

1 reference

Europe PubMed Central

4 November 2017

4 Pt 3

1 reference

Europe PubMed Central

4 November 2017

741-745

1 reference

Europe PubMed Central

4 November 2017

Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

An excitement subscale of the Positive and Negative Syndrome Scale

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

Olanzapine orally disintegrating tablet: a review of efficacy and compliance

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

Olanzapine versus haloperidol treatment in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

An open study of risperidone liquid in the acute phase of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970903166312

21 January 2018

Identifiers

10.1080/15622970903166312

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42631756&oldid=1963836608"